Cargando…

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease

The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) involvement in Alzheimer’s disease (AD) is poorly investigated. We evaluated the in vitro PCSK9 modulation of astrocyte cholesterol metabolism and neuronal cholesterol supplying, which is fundamental for neuronal functions. Moreover, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papotti, Bianca, Adorni, Maria Pia, Marchi, Cinzia, Zimetti, Francesca, Ronda, Nicoletta, Panighel, Giovanni, Lupo, Maria Giovanna, Vilella, Antonietta, Giuliani, Daniela, Ferri, Nicola, Bernini, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602670/ https://www.ncbi.nlm.nih.gov/pubmed/36293049 http://dx.doi.org/10.3390/ijms232012192

Ejemplares similares

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma
por: Adorni, Maria Pia, et al.
Publicado: (2022)

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives
por: Adorni, Maria Pia, et al.
Publicado: (2021)

HDL metabolism and functions impacting on cell cholesterol homeostasis are specifically altered in patients with abdominal aortic aneurysm
por: Adorni, Maria Pia, et al.
Publicado: (2022)

Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis
por: Karpouzas, George Athanasios, et al.
Publicado: (2022)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

Hydroxypropyl-β-Cyclodextrin Depletes Membrane Cholesterol and Inhibits SARS-CoV-2 Entry into HEK293T-ACE(hi) Cells
por: Alboni, Silvia, et al.
Publicado: (2023)

Statins influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
por: Karpouzas, George A., et al.
Publicado: (2023)

Inflammation and immunomodulatory therapies influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
por: Karpouzas, George A., et al.
Publicado: (2023)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies
por: Hokstad, Ingrid, et al.
Publicado: (2022)

Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021)

Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
por: Khalifa, Amr, et al.
Publicado: (2023)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

Author Correction: Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
por: Khalifa, Amr, et al.
Publicado: (2023)

HDL Proteome and Alzheimer’s Disease: Evidence of a Link
por: Marsillach, Judit, et al.
Publicado: (2020)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion
por: Zanotti, Ilaria, et al.
Publicado: (2013)

Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure
por: Bigazzi, Federico, et al.
Publicado: (2017)

Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review
por: Zimetti, Francesca, et al.
Publicado: (2021)

PCSK9 induces a pro-inflammatory response in macrophages
por: Ricci, Chiara, et al.
Publicado: (2018)

NMR, LC-MS Characterization of Rydingia michauxii Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9
por: Sut, Stefania, et al.
Publicado: (2022)

Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes
por: Ballerini, Patrizia, et al.
Publicado: (2006)

Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer’s disease
por: Turri, Marta, et al.
Publicado: (2023)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
por: Kamaruddin, Nurjannatul Naim, et al.
Publicado: (2021)

PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
por: Päth, Günter, et al.
Publicado: (2022)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Alcohol Pattern Consumption Differently Affects the Efficiency of Macrophage Reverse Cholesterol Transport in Vivo
por: Greco, Daniela, et al.
Publicado: (2018)

Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis
por: Kocyigit, Duygu, et al.
Publicado: (2021)

Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?
por: Ying, Qidi, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Cholesterol Regulates Exosome Release in Cultured Astrocytes
por: Abdullah, Mohammad, et al.
Publicado: (2021)

Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line
por: Lupo, Maria Giovanna, et al.
Publicado: (2020)

PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells
por: Greco, Maria Francesca, et al.
Publicado: (2022)

Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases
por: Clementino, Adryana Rocha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tc3phgpo4qc35m6ehlvtgu512t